[1] James C. 2014年全球生物技术/转基因作物商业化发展态势. 中国生物工程杂志, 2015, 35(1): 1-14. James C. Global status of commercialized biotech/GM crops: 2014. China Biotech, 2015, 35(1): 1-14.
[2] Barta A, Sommerqruber K, Thompson D, et al. The expression of a nopaline synthase - human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol Biol, 1986, 6(5): 347-357.
[3] Hiatt A, Cafferkey R,Bowdish K. Production of antibodies in transgenic plants. Nature, 1989, 342(6245): 76-78.
[4] Fujiwara T, Lessard P A, Beachy R N. Seed-specfic repression of GUS activity in tobacco plants by antisense RNA. Plant Mol Biol, 1992, 20(5): 1059-1069.
[5] Geng S, Ma M, Ye H C, et al. Anther-specific expression of ipt gene in transgenic tobacco and its effect on plant development. Transgenic Res, 2002, 11(3): 269-278.
[6] Van Haaren M J, Houck C M. A functional map of the fruit-specific promoter of the tomato 2A11 gene. Plant Molecular Biology, 1993, 21(4): 625-640.
[7] Liu Y W, Han C H, Lee M H, et al. Patatin, the tuber storage protein of potato (Solanum tuberosum L.), exhibits antioxidant activity in vitro. J Agric Food Chem, 2003, 51(15): 4389-4393.
[8] 周晓红, 陈晓光, 张晓东, 等. 番茄果实特异性E8启动子的基因克隆与序列分析. 第一军医大学学报, 2003, 23(1): 25-28. Zhou X H, Chen X G, Zhang X D, et al. Cloning and sequence analysis of tomato fruit-specific E8 promotor from Lycopersicon esculentum. J First Mil Med Univ, 2003, 23(1): 25-28.
[9] 王新力, 彭学贤. 香蕉果实成熟相关基因ACO1启动子区的克隆及其功能初探. 生物工程学报, 2001, 17(4): 428-431. Wang X L, Peng X X. Cloning of promotor of banana fruit ripening-related ACO1 and primary study on its function. Chinese Journal of Biotechnology, 2001, 17(4): 428-431.
[10] Stefan S, Neil E, Rainer F. Antibody molecular farming in plants and plant cells. Phytochemistry Reviews, 2002, 1(1): 45-54.
[11] ner T G. Metabolic Engineering Glycosylation: Biotechnology's Challenge to the Glycobiologist in the Next Millennium, in Carbohydrates in Chemistry and Biology. Germany: Wiley-VCH Verlag GmbH, 2000:1043-1064 .
[12] Kim T G, Kim H M, Lee H J, et al. Reduced protease activity in transformed rice cell suspension cultures expressing a proteinase inhibitor. Protein Expr Purif, 2007, 53(2):270-274.
[13] Rehbinder E, Engelhard M, Hagen K, et al. Pharming: Promises and risks of biopharmaceuticals derived from genetically modified plants and animals. Ethics of Science and Technology Assessment, 2008, 35: 1-341.
[14] Moloney M, Boothe J, Rooijen V, et al. Oil Bodies and Associated Proteins as Affinity Matrices: United States, 6509453. 2003-1-21.
[15] Stoger E, Sack M, Perrin Y, et al. Practical considerations for pharmaceutical antibody production in different crop systems. Mol Breed, 2002, 9(3): 149-158.
[16] 李翠玲, 崔继哲, 王洋, 等. 医药分子农业的受体系统评述. 分子植物育种, 2005, 3(1): 40-146. Li C L, Cui J Z, Wang Y, et al. The host system of medical molecular pharming. Molecular Plant Breeding, 2005, 3(1): 140-146.
[17] Mason H S, Lam D M, Arntzen C J. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci, 1992, 89(24): 11745-11749.
[18] Fischer R, Vaquero-Martin C, Sack M, et al. Towards molecular farming in the future:transient protein expression in plants. Biotechnol Appl Biochem, 1999, 30(2): 113-116.
[19] Shadwick F S, Doran P M. Infection, propagation, distribution and stability of plant virus in hairy root cultures. J Biotechnol, 2007, 131(3): 318-329.
[20] Márquez-Escobar V A, Tirado-Mendoza R, Noyola D E, et al. HRA2pI peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation. Planta, 2015, 242(1): 69-76.
[21] Fischer R, Emans N. Molecular farming of pharmaceutical proteins.Transgenic Res, 2000, 9(4-5): 279-299.
[22] Zhang G G, Rodrigues L, Rovinski B, et al. Production of HIV-1 p24 protein in transgenic tobacco plants. Mol Biotechnol, 2002, 20(2): 131-136.
[23] Daniell H, Khan M S, Allison L. Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci, 2002, 7(2): 84-91.
[24] Staub J M, Carcia B, Graves J, et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol, 2000, 18(3): 333-338.
[25] Fernández-San Millán A, Mingo-Castel A, Miller M, et al. A chloroplast transgenic approach to hyper-express and purify human serum albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol, 2003, 1(2): 77-79.
[26] Daniell H, Lee S B, Panchal T, et al. Expression of the native cholera B toxin subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol, 2001, 311(5): 1001-1009.
[27] Tregoning J S, Nixon P, Kuroda H, et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res, 2003, 31(4): 1174-1179.
[28] Leelavathi S, Gupta N, Maiti S, et al. Overproduction of an alkali- and thermo- stable xylanase in tobacco chloroplasts and efficient recovery of the enzyme. Mol Breed, 2003, 11(1): 59-67.
[29] Kay E, Vogel T M, Bertolla F, et al. Insitu transfer of antibiotic resistance genes from transgenic tobacco plants to bacteria. Appl Environ Microbiol, 2002, 68(7): 3345-3351.
[30] Jobling S A, Jarman C, Teh M M, et al. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat Biotechnol, 2003, 21(1): 77-80.
[31] Albarracín R M, Becher M L, Farran I, et al. The fusion of Toxoplasma gondii SAG1 vaccine candidate to Leishmania infantum heat shock protein 83-kDa improves expression levels in tobacco chloroplasts. Biotechnol J, 2015, 10(5): 748-759.
[32] Schillberg S, Zimmermann S, Findlay K, et al. Plasma membrane display of anti-viral single chain Fv fragments confers resistance to tobacco mosaic virus. Molecular Breeding, 2000, 6(3):317-326.
[33] Maldaner F R, Aragão F J, dos Santos F B, et al. Dengue virus tetra-epitope peptide expressed in lettuce chloroplasts for potential use in dengue diagnosis. Appl Microbiol Biotechnol, 2013, 97(13): 5721-5729.
[34] Chen X, Liu J. Generation and immunogenicity of transgenic potato expressing the GP5 protein of porcine reproductive and respiratory syndrome virus. J Virol Methods, 2011, 173(1): 153-158.
[35] De Guzman G, Walmsley A M, Webster D E, et al. Hairy roots cultures from different Solanaceous species have varying capacities to produce E. coli B-subunit heat-labile toxin antigen. Biotechnol Lett, 2011, 33(12): 2495-2502.
[36] Hood E E, Witcher D R, Maddock S. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breed, 1997, 3(4): 291-306.
[37] Witcher D R, Hood E E, Peterson D, et al. Commercial production of β-glucuronidase(GUS): a model system for the production of proteins in plants. Mol Breed, 1998, 4(4): 301-312.
[38] Hood E E, Woodard S L, Horn M E. Monoclonal antibody manufacturing in transgenic plants- myths and realities. Curr Opin Biotechnol, 2002, 13(6): 630-635.
[39] Elizabeth E H. From green plants to industrial enzymes. Enzyme & Microbial Technol, 2002, 30(3): 279-283.
[40] Guerrero-Andrade O, Loza-Rubio E, Olivera-Flores T, et al. Expression of the Newcastle disease virus fusion protein in transgenic maize and immunological studies. Transgenic Res, 2006, 15(4): 455-463.
[41] Stöger E, Vaquero C, Torres E, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol, 2000, 42(4): 583-590.
[42] Fu G, Grbic V, Ma S, et al. Evaluation of somatic embryos of alfalfa for recombinant protein expression. Plant Cell Rep, 2015, 34(2): 211-221.
[43] Giddings G. Transgenic plants as protein factories. Curr Opin Biotechnol, 2001, 12(5): 450-454.
[44] Agres T. Global Pharmaceutical Market to Double in Value to US$1.3 Trillion by 2020 PharmaAsia. .http://www.pharmaasia.com/2007/08/report-global-pharmaceutical-market-to-double-in-value-to-us1-3-trillion-by-2020/. |